ArticleJournal of substance abuse treatment2021
It's not just the money: The role of treatment ideology in publicly funded substance use disorder treatment.
Article in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (Helping End Addiction Long-Term®) communities study.Preventive medicine · 2024Trial
- Enhancing Use of Medications for Opioid Use Disorder Through External Coaching.Psychiatric services (Washington, D.C.) · 2023Trial
- "They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs.Addiction science & clinical practice · 2025Article
- Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug and alcohol dependence · 2025Article
- "We need all hands on deck": characterizing addiction medicine training in Canada-a mixed methods study of fellowship program directors.Addiction science & clinical practice · 2025Article
- Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data.Journal of substance use and addiction treatment · 2025Article
- Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.Journal of substance use and addiction treatment · 2024Article
- Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.Journal of substance use and addiction treatment · 2023Article
- Tailoring dissemination strategies to increase evidence-informed policymaking for opioid use disorder treatment: study protocol.Implementation science communications · 2023Article
- Not in my treatment center: Leadership's perception of barriers to MOUD adoption.Journal of substance abuse treatment · 2023Article
- Residential treatment and medication treatment for opioid use disorder: The role of state Medicaid innovations in advancing the field.Drug and alcohol dependence reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Medications for opioid use disorder (MOUD) are a first-line treatment for opioid use disorder, yet national surveys indicate that most substance use treatment facilities do not offer MOUD. This article presents the results of a qualitative analysis of interviews with leaders from 25 treatment organizations in Philadelphia, Pennsylvania, that investigated attitudes and barriers toward MOUD. Most treatment organizations that we interviewed are adopting at least one MOUD, suggesting that Philadelphia exceeds the national average of organizations with MOUD capacity. Leaders indicated that both practical resources and ideological barriers thwart adoption and implementation of MOUD in publicly funded substance use disorder treatment agencies. Organizations that had recently adopted MOUDs revealed facilitators to MOUD adoption, such as strong leadership that champions the implementation to staff and redefining recovery from substance use disorders throughout the organization. This study's findings highlight that clients, clinicians, and leadership need to address both practical and ideological barriers to expanding MOUD use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.